Arcus Biosciences, a clinical-stage biopharmaceutical company headquartered in Hayward, California is advancing the development of innovative cancer therapies. The company is currently focused on several pipeline products, including Domvanalimab, an anti-TIGIT investigational monoclonal antibody in Phase 2 and Phase 3 clinical trials, AB308 - another anti-TIGIT monoclonal antibody in Phase 1b clinical trials, Etrumadenant, a dual A2a/A2b adenosine receptor antagonist in Phase 2 clinical trials, Quemliclustat - a small-molecule CD73 inhibitor in Phase 1b and Phase 2 clinical trials, Zimberelimab - an anti-PD-1 antibody in Phase 2 clinical trials for metastatic cell lung cancer and monotherapy, and AB521, an oral and small-molecule inhibitor of HIF-2a in Phase 1 clinical trials for the treatment of Von Hippel-Lindau disease. The company also has a clinical collaboration with AstraZeneca to evaluate domvanalimab in combination with durvalumab in a registrational phase 3 clinical trial for patients with unresectable Stage 3 NSCLC. Additionally, BVF Partners L.P. is supporting the company's discovery and development of compounds for the treatment of inflammatory diseases.